Pfizer Inc. (NYSE:PFE) Stock Holdings Increased by Jaffetilchin Investment Partners LLC

Jaffetilchin Investment Partners LLC lifted its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 217.6% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 100,764 shares of the biopharmaceutical company's stock after purchasing an additional 69,035 shares during the quarter. Jaffetilchin Investment Partners LLC's holdings in Pfizer were worth $2,673,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. PSI Advisors LLC increased its holdings in Pfizer by 1.4% in the 4th quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company's stock valued at $738,000 after purchasing an additional 385 shares in the last quarter. Patriot Financial Group Insurance Agency LLC boosted its holdings in Pfizer by 1.0% in the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company's stock worth $1,027,000 after acquiring an additional 391 shares during the period. D Orazio & Associates Inc. grew its position in Pfizer by 5.5% in the fourth quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company's stock valued at $200,000 after acquiring an additional 391 shares in the last quarter. Lipe & Dalton boosted its stake in shares of Pfizer by 17.7% in the fourth quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company's stock valued at $71,000 after purchasing an additional 400 shares during the period. Finally, Oliver Luxxe Assets LLC grew its holdings in Pfizer by 2.2% during the 4th quarter. Oliver Luxxe Assets LLC now owns 18,811 shares of the biopharmaceutical company's stock valued at $499,000 after purchasing an additional 401 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on PFE. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Truist Financial dropped their price objective on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, December 18th. The Goldman Sachs Group reiterated a "neutral" rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Citigroup restated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Finally, Guggenheim reissued a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $31.07.

Pfizer Stock Performance

Shares of Pfizer stock traded up $0.19 on Monday, reaching $22.10. 61,845,565 shares of the company were exchanged, compared to its average volume of 40,318,640. The firm has a market cap of $125.34 billion, a price-to-earnings ratio of 15.67, a P/E/G ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company's 50-day moving average is $25.25 and its two-hundred day moving average is $26.38.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter in the previous year, the company posted $0.10 earnings per share. The company's revenue for the quarter was up 24.7% compared to the same quarter last year. As a group, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Insider Activity

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction dated Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.06% of the company's stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.